Literature DB >> 9049784

Gamma delta T lymphocytosis associated with common variable immunodeficiency.

R K Katial1, M M Lieberman, S L Muehlbauer, J A Lust, D L Hamilos.   

Abstract

We present the case of a 28-year-old Caucasian female with common variable immunodeficiency (CVID) since age 5 who had a long history of hospitalizations for unexplained fevers and pulmonary infiltrates. The patient developed mild lymphocytosis 7 months prior to our evaluation. Flow cytometry of peripheral blood revealed an expansion of gamma delta T lymphocytes, mild CD4 T lymphocytopenia, and a reduced CD4/CD8 ratio (0.2). Two subpopulations of gamma delta T lymphocytes were found (CD3+/CD4-/CD8+, 47%; CD3+/CD4-/CD8-, 53%), the vast majority of which expressed V-delta 1. An infectious cause for the patient's gamma delta T lymphocytosis could not be found. The sputum was chronically colonized with Staphylococcus aureus, and the organism produced TSST-1 in vitro. A bronchoalveolar lavage (BAL) revealed marked lymphocytosis, but gamma delta T lymphocytes were not overrepresented in the BAL. Lymphocyte functional studies revealed poor proliferative responses to mitogens and staphylococcal superantigens and diminished cytokine production. V-delta 1 T lymphocytes from the patient's blood were not expanded in vitro in response to staphylococcal superantigens. TCR gene rearrangement studies confirmed the presence of J gamma and J beta 1 clonal rearrangements accounting for only a small subpopulation of the gamma delta T lymphocytes. These studies were repeated 5 months later and were unchanged. A bone marrow biopsy was negative for leukemia. Hence, the cause of the patient's gamma delta T lymphocytosis could not be determined despite evaluation for underlying malignancy, occult infection, or superantigen-driven stimulation. The patient ultimately died of progressive respiratory insufficiency. The state of current knowledge regarding gamma delta T lymphocytosis, decreased production of alpha beta T lymphocytes, and a low CD4/ CD8 ratio in association with CVID is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049784     DOI: 10.1023/a:1027384311897

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  28 in total

Review 1.  Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1990-05

2.  T-cell receptor gamma delta and gamma transgenic mice suggest a role of a gamma gene silencer in the generation of alpha beta T cells.

Authors:  I Ishida; S Verbeek; M Bonneville; S Itohara; A Berns; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

3.  B cell function in acquired "common-variable" hypogammaglobulinemia: proliferative responses to lymphokines.

Authors:  J Farrant; A Bryant; F Almandoz; G Spickett; S W Evans; A D Webster
Journal:  Clin Immunol Immunopathol       Date:  1989-05

4.  Identification of a putative second T-cell receptor.

Authors:  M B Brenner; J McLean; D P Dialynas; J L Strominger; J A Smith; F L Owen; J G Seidman; S Ip; F Rosen; M S Krangel
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

5.  Lymphocytic interstitial pneumonia of common variable immunodeficiency.

Authors:  V Popa
Journal:  Ann Allergy       Date:  1988-03

6.  Three distinct stages of B-cell defects in common varied immunodeficiency.

Authors:  O Saiki; P Ralph; C Cunningham-Rundles; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Rearrangement of the T-cell receptor delta genes in human T-cell leukemias.

Authors:  L Foroni; M Laffan; T Boehm; T H Rabbitts; D Catovsky; L Luzzatto
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

8.  T cell receptor gamma/delta+ lymphocyte subsets during HIV infection.

Authors:  B Autran; F Triebel; C Katlama; W Rozenbaum; T Hercend; P Debre
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

9.  Blockage of alpha beta T-cell development by TCR gamma delta transgenes.

Authors:  M Bonneville; I Ishida; P Mombaerts; M Katsuki; S Verbeek; A Berns; S Tonegawa
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

10.  Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire.

Authors:  C M Parker; V Groh; H Band; S A Porcelli; C Morita; M Fabbi; D Glass; J L Strominger; M B Brenner
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  5 in total

1.  Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent hosts.

Authors:  R K Katial; D Sachanandani; C Pinney; M M Lieberman
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

2.  Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells.

Authors:  A M Holm; E A Sivertsen; S H Tunheim; T Haug; V Bjerkeli; A Yndestad; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

3.  Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome.

Authors:  L E Leiva; J Junprasert; D Hollenbaugh; R U Sorensen
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 4.  Diagnostic role of tests for T cell receptor (TCR) genes.

Authors:  E Hodges; M T Krishna; C Pickard; J L Smith
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

5.  Inversion of the Vδ1 to Vδ2 γδ T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion.

Authors:  Dominic Paquin-Proulx; Nathália Silveira Barsotti; Bianca A N Santos; Ana Karolina B B Marinho; Cristina M Kokron; Karina I Carvalho; Myrthes T Barros; Jorge Kalil; Douglas F Nixon; Esper G Kallas
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.